Monopar Therapeutics (MNPR) Other Non-Current Assets (2016 - 2021)

Monopar Therapeutics has disclosed Other Non-Current Assets across 6 years of filings, most recently posting $68858.0 for Q3 2021.

• Other Non-Current Assets for Q3 2021 came in at $68858.0, changed 0.0% year-over-year; the trailing twelve-month figure through Sep 2021 was $68858.0 (changed 0.0% YoY), and the FY2020 annual result was $68858.0, down 43.73% from the prior year.
• Other Non-Current Assets came in at $68858.0 for Q3 2021 at Monopar Therapeutics, roughly flat from $68858.0 in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $800031.0 in Q4 2017 to a low of $65731.0 in Q4 2018.
• The 5-year median for Other Non-Current Assets is $70954.0 (2020), against an average of $260660.5.
• Across the five-year window, Other Non-Current Assets plunged 91.78% in 2018 and surged 86.18% in 2019, its largest moves.
• Monopar Therapeutics' Other Non-Current Assets stood at $800031.0 in 2017, then slumped by 91.78% to $65731.0 in 2018, then soared by 86.18% to $122381.0 in 2019, then plunged by 43.73% to $68858.0 in 2020, then changed by 0.0% to $68858.0 in 2021.
• The last three Other Non-Current Assets figures came in at $68858.0 (Q3 2021), $68858.0 (Q2 2021), and $68858.0 (Q1 2021), per Business Quant data.